Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.

Beckmann, KR; Bangma, CH; Helleman, J; Bjartell, A; Carroll, PR; Morgan, T; Nieboer, D; Santaolalla, A; Trock, BJ; Valdagni, R; Roobol, MJ; Global Action Plan Active Surveillance Prostate Cancer [G.A.P.3] Consortium,

Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.

Beckmann, KR Bangma, CH Helleman, J Bjartell, A Carroll, PR Morgan, T Nieboer, D Santaolalla, A Trock, BJ Valdagni, R Roobol, MJ Global Action Plan Active Surveillance Prostate Cancer [G.A.P.3] Consortium,

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: The Prostate, 2022, 82, (7), pp. 876-879
Issue Date:: 2022-05

Closed Access

	Filename	Description	Size
	The Prostate - 2022 - Beckmann - Comparison of outcomes of different biopsy schedules among men on active surveillance for.pdf		219.94 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Beckmann, KR
dc.contributor.author	Bangma, CH
dc.contributor.author	Helleman, J
dc.contributor.author	Bjartell, A
dc.contributor.author	Carroll, PR
dc.contributor.author	Morgan, T
dc.contributor.author	Nieboer, D
dc.contributor.author	Santaolalla, A
dc.contributor.author	Trock, BJ
dc.contributor.author	Valdagni, R
dc.contributor.author	Roobol, MJ
dc.contributor.author	Global Action Plan Active Surveillance Prostate Cancer [G.A.P.3] Consortium,
dc.date.accessioned	2022-10-11T03:16:56Z
dc.date.available	2022-02-21
dc.date.available	2022-10-11T03:16:56Z
dc.date.issued	2022-05
dc.identifier.citation	The Prostate, 2022, 82, (7), pp. 876-879
dc.identifier.issn	0270-4137
dc.identifier.issn	1097-0045
dc.identifier.uri	http://hdl.handle.net/10453/162461
dc.description.abstract	BACKGROUND: The optimal interval for repeat biopsy during active surveillance (AS) for prostate cancer is yet to be defined. This study examined whether risk of upgrading (to grade group ≥ 2) or risk of converting to treatment varied according to intensity of repeat biopsy using data from the GAP3 consortium's global AS database. MATERIALS AND METHODS: Intensity of surveillance biopsy schedules was categorized according to centers' protocols: (a) Prostate Cancer Research International Active Surveillance project (PRIAS) protocols with biopsies at years 1, 4, and 7 (10 centers; 7532 men); (b) biennial biopsies, that is, every other year (8 centers; 4365 men); and (c) annual biopsy schedules (4 centers; 1602 men). Multivariable Cox regression was used to compare outcomes according to biopsy intensity. RESULTS: Out of the 13,508 eligible participants, 56% were managed according to PRIAS protocols (biopsies at years 1, 4, and 7), 32% via biennial biopsy, and 12% via annual biopsy. After adjusting for baseline characteristics, risk of converting to treatment was greater for those on annual compared with PRIAS biopsy schedules (hazard ratio [HR] = 1.66; 95% confidence interval [CI] = 1.51-1.83; p < 0.001), while risk of upgrading did not differ (HR = 0.96; 95% CI = 0.84-1.10). CONCLUSION: Results suggest more frequent biopsy schedules may deter some men from continuing AS despite no evidence of grade progression.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Wiley
dc.relation.ispartof	The Prostate
dc.relation.isbasedon	10.1002/pros.24330
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1103 Clinical Sciences, 1112 Oncology and Carcinogenesis, 1114 Paediatrics and Reproductive Medicine
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.mesh	Biopsy
dc.subject.mesh	Disease Progression
dc.subject.mesh	Humans
dc.subject.mesh	Male
dc.subject.mesh	Neoplasm Grading
dc.subject.mesh	Prostate
dc.subject.mesh	Prostate-Specific Antigen
dc.subject.mesh	Prostatic Neoplasms
dc.subject.mesh	Watchful Waiting
dc.subject.mesh	Biopsy
dc.subject.mesh	Disease Progression
dc.subject.mesh	Humans
dc.subject.mesh	Male
dc.subject.mesh	Neoplasm Grading
dc.subject.mesh	Prostate
dc.subject.mesh	Prostate-Specific Antigen
dc.subject.mesh	Prostatic Neoplasms
dc.subject.mesh	Watchful Waiting
dc.subject.mesh	Prostate
dc.subject.mesh	Humans
dc.subject.mesh	Prostatic Neoplasms
dc.subject.mesh	Disease Progression
dc.subject.mesh	Prostate-Specific Antigen
dc.subject.mesh	Biopsy
dc.subject.mesh	Male
dc.subject.mesh	Watchful Waiting
dc.subject.mesh	Neoplasm Grading
dc.title	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.
dc.type	Journal Article
utslib.citation.volume	82
utslib.location.activity	United States
utslib.for	1103 Clinical Sciences
utslib.for	1112 Oncology and Carcinogenesis
utslib.for	1114 Paediatrics and Reproductive Medicine
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Public Health
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2022-10-11T03:16:55Z
pubs.issue	7
pubs.publication-status	Published
pubs.volume	82
utslib.citation.issue	7

Abstract:

BACKGROUND: The optimal interval for repeat biopsy during active surveillance (AS) for prostate cancer is yet to be defined. This study examined whether risk of upgrading (to grade group ≥ 2) or risk of converting to treatment varied according to intensity of repeat biopsy using data from the GAP3 consortium's global AS database. MATERIALS AND METHODS: Intensity of surveillance biopsy schedules was categorized according to centers' protocols: (a) Prostate Cancer Research International Active Surveillance project (PRIAS) protocols with biopsies at years 1, 4, and 7 (10 centers; 7532 men); (b) biennial biopsies, that is, every other year (8 centers; 4365 men); and (c) annual biopsy schedules (4 centers; 1602 men). Multivariable Cox regression was used to compare outcomes according to biopsy intensity. RESULTS: Out of the 13,508 eligible participants, 56% were managed according to PRIAS protocols (biopsies at years 1, 4, and 7), 32% via biennial biopsy, and 12% via annual biopsy. After adjusting for baseline characteristics, risk of converting to treatment was greater for those on annual compared with PRIAS biopsy schedules (hazard ratio [HR] = 1.66; 95% confidence interval [CI] = 1.51-1.83; p < 0.001), while risk of upgrading did not differ (HR = 0.96; 95% CI = 0.84-1.10). CONCLUSION: Results suggest more frequent biopsy schedules may deter some men from continuing AS despite no evidence of grade progression.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/162461